NCT00398905 - Dose-Ranging Study of BAY 59-7939 on the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement | Biotech Hunter

Enrollment

726

Participants

Timeline

Start Date

January 31, 2004

Study Completion Date

September 30, 2004

Conditions

Venous Thromboembolism

Interventions

DRUG

Rivaroxaban (Xarelto, BAY59-7939)

2,5 mg twice daily (5 mg total daily dose)

DRUG

Rivaroxaban (Xarelto, BAY59-7939)

5 mg twice daily (10 mg total daily dose)

DRUG

Rivaroxaban (Xarelto, BAY59-7939)

10 mg twice daily (20 mg total daily dose)

DRUG

Rivaroxaban (Xarelto, BAY59-7939)

20 mg twice daily (40 mg total daily dose)

DRUG

Rivaroxaban (Xarelto, BAY59-7939)

30 mg twice daily (60 mg total daily dose)

DRUG

Enoxaparin

40 mg once daily (40 mg total daily dose)

Trial Locations (61)

1020

Bruxelles - Brussel

1220

Vienna

2700

Wiener Neustadt

2730

Herlev

2900

Hellerup

3600

Genk

3800

Sint-Truiden

4010

Linz

4500

Huy

7331

Baudour

8600

Silkeborg

14165

Berlin

16766

Sommerfeld

20089

Rozzano

20132

Milan

21100

Varese

27100

Pavia

31096

Haifa

35043

Marburg

40225

Düsseldorf

42100

Reggio Emilia

46010

Valencia

52621

Tel Litwinsky

59037

Lille

60528

Frankfurt am Main

64239

Tel Aviv

65929

Frankfurt am Main

70300

Ẕerifin

79618

Rheinfelden

80030

Amiens

82467

Garmisch-Partenkirchen

86000

Poitiers

89075

Ulm

90766

Fürth

DK-2970

Hørsholm

01307

Dresden

06024

Gubbio

06122

Perugia

1213 XZ

Hilversum

6522 JV

Nijmegen

6131 BK

Sittard

NO-8005

Bodø

NO-3019

Drammen

NO-3675

Notodden

0440

Oslo

NO-3660

Rjukan

15-276

Bialystok

80-742

Gdansk

31-826

Krakow

91-425

Lodz

20-090

Lublin

20-718

Lublin

00-909

Warsaw

08916

Badalona

08035

Barcelona

08036

Barcelona

416 85

Gothenburg

301 85

Halmstad

551 85

Jönköping

442 83

Kungälv

SE5 9RS

London